Presence Of Patient Experience Data Table In FDA Drug Review Summaries ‘Inconsistent’

RTI Health Solutions researchers assessed US FDA review documents over past two years to gauge use of a tool meant to facilitate agency disclosures about what patient experience information it considered.

Medical technology, telemedicine, e-health, medical online, electronics health record system concept. male doctor working on digital tablet computer with web icons technology on virtual screen.
A Patient Experience Data Checklist For Review Summaries

The US Food and Drug Administration is making progress with its implementation of a patient experience data summary section in new drug review documents but there are still inconsistencies, RTI Health Solutions' Ari Gnanasakthy reported at ISPOR's recent annual meeting.

The patient experience data table outlines whether and what patient experience data had been submitted with an application. The FDA...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA

PS-AgencyLeadership (Premium-1): Study Reveals How Immune System of Astronauts Breaks Down

Recent studies show that spaceflight can significantly weaken astronauts’ immune systems, making them more susceptible to infections and health complications during and after missions. Understanding these changes is crucial for ensuring the safety of future long-duration space travelers.

Nancy Test Circulable Section Geography

 

This is a short description

New US FDA Adcomm Trend: Approved Cancer Meds Get Another Look When Competitors Coming

 

Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.

Califf: Not Wise To Create Problems Related to Chinese Pharma Supply Chain Dependence

 

The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.

More from Agency Leadership

New US FDA Adcomm Trend: Approved Cancer Meds Get Another Look When Competitors Coming

 

Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.

Califf: Not Wise To Create Problems Related to Chinese Pharma Supply Chain Dependence

 

The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.